Ensifentrine for COPD
CHEST Journal,
Год журнала:
2025,
Номер
167(2), С. 305 - 306
Опубликована: Фев. 1, 2025
Язык: Английский
Ensifentrine vs placebo for chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized clinical trials
Expert Review of Respiratory Medicine,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 19, 2025
To
evaluate
the
efficacy
and
safety
of
ensifentrine
in
chronic
obstructive
pulmonary
disease
(COPD).
We
searched
electronic
databases
registries
until
25
January
2025,
for
randomized
clinical
trials
(RCTs)
comparing
vs
placebo
patients
with
COPD.
Primary
outcomes
include
forced
expiratory
volume
one
second
(FEV₁)
area
under
curve
(AUC),
peak
FEV₁,
morning
trough
FEV₁.
Ten
RCTs
involving
2,589
were
included.
Compared
placebo,
improved
FEV₁
AUC
by
104.24
ml
(95%
CI,
74.03
to
133.44;
moderate
certainty)
on
day
1
90.37
54.94
125.81;
at
study
end.
Ensifentrine
increased
140.99
107.48
174.5;
118.98
final
assessment
86.49
151.47;
certainty).
42.15
19.87
64.43;
high
Dose-response
analysis
showed
a
bell-shaped
all
outcomes.
did
not
significantly
differ
from
adverse
events
or
improvements
COPD
symptoms
quality
life.
lung
function
Larger
are
needed
integrate
this
bronchodilator
benefit
patient-centered
CRD42024571928.
Язык: Английский
The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease
Expert Review of Clinical Pharmacology,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 3, 2024
Introduction
The
therapeutic
implications
of
phosphodiesterase
(PDE)
inhibitors
have
attracted
interest
because
PDEs
are
regarded
as
an
intracellular
target
to
be
exploited
for
advancements
in
the
treatment
COPD.
At
present,
only
approved
approach
COPD
with
PDE
is
use
oral
PDE4
inhibitor.
However,
this
not
widely
employed,
primarily
due
narrow
index
associated
inhibitors,
which
considerably
restricts
permissible
dosage.
inhalation
route
represents
a
viable
alternative
improving
inhibitors.
Язык: Английский